Trial Profile

Botensilimab and Balstilimab Expanded Access Program

Status: Recruiting

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 02 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Balstilimab (Primary) ; Botensilimab (Primary)
Indications Colorectal cancer; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Sarcoma
Focus Expanded access; Therapeutic Use
Sponsors Agenus

Most Recent Events

10 Nov 2025 Accoridng to Agenus media release, in September, Francemedicines agency (ANSM) authorized reimbursed compassionate access (Access Compassionnel, AAC) for BOT/BAL in refractory MSS mCRC without active liver metastases
07 Jan 2025 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com